## Yaguang Xi

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8943817/publications.pdf Version: 2024-02-01



ΥΛΟΠΑΝΟ ΧΙ

#	Article	IF	CITATIONS
1	Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. Rna, 2007, 13, 1668-1674.	1.6	506
2	The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Medical Genomics, 2008, 1, 13.	0.7	425
3	Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene, 2009, 28, 4065-4074.	2.6	384
4	MicroRNA-125b Confers the Resistance of Breast Cancer Cells to Paclitaxel through Suppression of Pro-apoptotic Bcl-2 Antagonist Killer 1 (Bak1) Expression. Journal of Biological Chemistry, 2010, 285, 21496-21507.	1.6	370
5	MiR-200, a new star miRNA in human cancer. Cancer Letters, 2014, 344, 166-173.	3.2	303
6	Prognostic Values of microRNAs in Colorectal Cancer. Biomarker Insights, 2006, 2, 113-121.	1.0	223
7	Differentially Regulated Micro-RNAs and Actively Translated Messenger RNA Transcripts by Tumor Suppressor p53 in Colon Cancer. Clinical Cancer Research, 2006, 12, 2014-2024.	3.2	191
8	CRISPR/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo. Scientific Reports, 2016, 6, 22312.	1.6	174
9	<i>miR-192</i> Regulates Dihydrofolate Reductase and Cellular Proliferation through the p53-microRNA Circuit. Clinical Cancer Research, 2008, 14, 8080-8086.	3.2	145
10	Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics and Proteomics, 2006, 3, 317-324.	1.0	144
11	Hypoxia-regulated microRNAs in human cancer. Acta Pharmacologica Sinica, 2013, 34, 336-341.	2.8	128
12	MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death and Differentiation, 2012, 19, 378-386.	5.0	117
13	Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/β-Catenin Signaling. Molecular Cancer Therapeutics, 2013, 12, 1848-1859.	1.9	113
14	Systematic Evaluation of Three microRNA Profiling Platforms: Microarray, Beads Array, and Quantitative Real-Time PCR Array. PLoS ONE, 2011, 6, e17167.	1.1	95
15	Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer. Breast Cancer Research, 2008, 10, R22.	2.2	93
16	A Novel Sulindac Derivative that Potently Suppresses Colon Tumor Cell Growth by Inhibiting cGMP Phosphodiesterase and β-Catenin Transcriptional Activity. Cancer Prevention Research, 2012, 5, 822-833.	0.7	83
17	Human snoRNA-93 is processed into a microRNA-like RNA that promotes breast cancer cell invasion. Npj Breast Cancer, 2017, 3, 25.	2.3	74
18	Panepoxydone Targets NF-kB and FOXM1 to Inhibit Proliferation, Induce Apoptosis and Reverse Epithelial to Mesenchymal Transition in Breast Cancer. PLoS ONE, 2014, 9, e98370.	1.1	70

YAGUANG XI

#	Article	IF	CITATIONS
19	LncDisease: a sequence based bioinformatics tool for predicting lncRNA-disease associations. Nucleic Acids Research, 2016, 44, e90-e90.	6.5	70
20	Nmi (Nâ€Myc interactor) inhibits Wnt/βâ€catenin signaling and retards tumor growth. International Journal of Cancer, 2009, 125, 556-564.	2.3	68
21	Sulindac inhibits tumor cell invasion by suppressing NF-ήB-mediated transcription of microRNAs. Oncogene, 2012, 31, 4979-4986.	2.6	68
22	Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Experimental Cell Research, 2008, 314, 2110-2122.	1.2	66
23	Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity. Oncogene, 2015, 34, 1499-1509.	2.6	54
24	Metformin and cancer immunity. Acta Pharmacologica Sinica, 2020, 41, 1403-1409.	2.8	54
25	Spheroidâ€forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry <i>via</i> hsaâ€miRâ€299–5p regulated <i>de novo</i> expression of osteopontin. Journal of Cellular and Molecular Medicine, 2010, 14, 1693-1706.	1.6	50
26	p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis, 2004, 25, 2201-2206.	1.3	42
27	MicroRNA in Melanoma. Ochsner Journal, 2010, 10, 83-92.	0.5	40
28	A personalized microRNA microarray normalization method using a logistic regression model. Bioinformatics, 2010, 26, 228-234.	1.8	37
29	Aquaporins mediate the chemoresistance of human melanoma cells to arsenite. Molecular Oncology, 2012, 6, 81-87.	2.1	37
30	Association of insulin-like growth factor binding protein-3 expression with melanoma progression. Molecular Cancer Therapeutics, 2006, 5, 3078-3084.	1.9	35
31	Role of RUNX3 in Suppressing Metastasis and Angiogenesis of Human Prostate Cancer. PLoS ONE, 2014, 9, e86917.	1.1	35
32	Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics, 2006, 7, 68.	1.2	34
33	Gene Expression Profiles Classify Human Osteosarcoma Xenografts According to Sensitivity to Doxorubicin, Cisplatin, and Ifosfamide. Clinical Cancer Research, 2009, 15, 7161-7169.	3.2	34
34	MicroRNA and Cancer Chemoprevention. Cancer Prevention Research, 2013, 6, 401-409.	0.7	34
35	Challenges for MicroRNA Microarray Data Analysis. Microarrays (Basel, Switzerland), 2013, 2, 34-50.	1.4	34
36	Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Oncology Reports, 2008, 19, 257-62.	1.2	34

YAGUANG XI

#	Article	IF	CITATIONS
37	CDH11 expression is associated with survival in patients with osteosarcoma. Cancer Genomics and Proteomics, 2008, 5, 37-42.	1.0	34
38	Reduction of Orc6 Expression Sensitizes Human Colon Cancer Cells to 5-Fluorouracil and Cisplatin. PLoS ONE, 2008, 3, e4054.	1.1	32
39	Anticancer bioactive peptides suppress human colorectal tumor cell growth and induce apoptosis via modulating the PARP-p53-Mcl-1 signaling pathway. Acta Pharmacologica Sinica, 2015, 36, 1514-1519.	2.8	28
40	Cav3.1 (α1G) controls von Willebrand factor secretion in rat pulmonary microvascular endothelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L833-L844.	1.3	26
41	MicroRNAs are involved in the development and progression of gastric cancer. Acta Pharmacologica Sinica, 2021, 42, 1018-1026.	2.8	25
42	The Impact of Genomics in Understanding Human Melanoma Progression and Metastasis. Cancer Control, 2008, 15, 202-215.	0.7	24
43	Translational control analysis by translationally active RNA capture/microarray analysis (TrIP–Chip). Nucleic Acids Research, 2010, 38, e104-e104.	6.5	23
44	Prognostic Values of microRNAs in Colorectal Cancer. Biomarker Insights, 2006, 1, 117727190600100.	1.0	22
45	MicroRNAs are involved in the self-renewal and differentiation of cancer stem cells. Acta Pharmacologica Sinica, 2013, 34, 1374-1380.	2.8	22
46	Methylation of the miR-126 gene associated with glioma progression. Familial Cancer, 2016, 15, 317-324.	0.9	19
47	Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma. Clinical and Experimental Metastasis, 2009, 26, 739-749.	1.7	18
48	Thiazide-sensitive Na <sup>+</sup> –Cl <sup>−cotransporter: genetic polymorphisms and human diseases. Acta Biochimica Et Biophysica Sinica, 2015, 47, 325-334.</sup>	amp;gt;	18
49	MicroRNAs and anticancer drugs. Acta Biochimica Et Biophysica Sinica, 2014, 46, 233-239.	0.9	17
50	Investigation of miRNA biology by bioinformatic tools and impact of miRNAs in colorectal cancer-regulatory relationship of c-Myc and p53 with miRNAs. Cancer Informatics, 2007, 3, 245-53.	0.9	17
51	MicroRNAs mediate therapeutic and preventive effects of natural agents in breast cancer. Chinese Journal of Natural Medicines, 2016, 14, 881-887.	0.7	16
52	MicroRNA, epigenetic machinery and lung cancer. Thoracic Cancer, 2011, 2, 35-44.	0.8	14
53	SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro. Oncology Reports, 2014, 32, 2533-2540.	1.2	14
54	Triphenylmethyl Derivatives Enhances the Anticancer Effect of Immunotoxins. Journal of Immunotherapy, 2011, 34, 438-447.	1.2	13

YAGUANG XI

#	Article	IF	CITATIONS
55	Inhibition of breast cancer cell motility with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGFβ/miR-21 signaling. Oncotarget, 2016, 7, 7979-7992.	0.8	12
56	Investigation of miRNA Biology by Bioinformatic Tools and Impact of miRNAs in Colorectal Cancer—Regulatory Relationship of c-Myc and p53 with miRNAs. Cancer Informatics, 2007, 3, 117693510700300.	0.9	11
57	MicroRNA provides insight into understanding esophageal cancer. Thoracic Cancer, 2011, 2, 134-142.	0.8	9
58	Normalizing bead-based microRNA expression data: a measurement error model-based approach. Bioinformatics, 2011, 27, 1506-1512.	1.8	9
59	Global comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenografts. Cancer Genomics and Proteomics, 2008, 5, 1-35.	1.0	9
60	Entecavir Versus Lamivudine Therapy for Patients With Chronic Hepatitis B-Associated Liver Failure: A Meta-Analysis. Hepatitis Monthly, 2014, 14, e19164.	0.1	8
61	MicroRNA-like snoRNA-Derived RNAs (sdRNAs) Promote Castration-Resistant Prostate Cancer. Cells, 2022, 11, 1302.	1.8	8
62	CRISPR/Cas9 ablating viral microRNA promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus. Biochemical and Biophysical Research Communications, 2020, 533, 1400-1405.	1.0	7
63	MicroRNA: A New Player for Cancer Chemoprevention. Journal of Integrative Oncology, 2013, 02, .	0.3	6
64	Bax is involved in the anticancer activity of Velcade in colorectal cancer. Experimental and Therapeutic Medicine, 2017, 14, 3179-3183.	0.8	5
65	Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer. Genes and Diseases, 2021, 8, 320-330.	1.5	5
66	Mechanistic Role of MicroRNA in Cancer Chemoprevention by Nonsteroidal Anti-inflammatory Drugs. Current Pharmacology Reports, 2015, 1, 154-160.	1.5	4
67	Esophageal cancer in Chinese population: no polymorphism in codon 149 of P21Waf1/Cip1 cyclin dependent kinase gene. Oncogene, 2002, 21, 7745-7748.	2.6	3
68	Testing for Differentially-Expressed MicroRNAs with Errors-in-Variables Nonparametric Regression. PLoS ONE, 2012, 7, e37537.	1.1	3
69	CRISPR/Cas9 System to Knockdown MicroRNA In Vitro and In Vivo. Methods in Molecular Biology, 2021, 2300, 133-139.	0.4	3
70	Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti–PD-L1 Immunotherapy. Molecular Cancer Therapeutics, 2021, 20, 1295-1304.	1.9	2
71	Genetic Editing of Long Noncoding RNA Using Technology. Methods in Molecular Biology, 2021, 2372, 169-177.	0.4	0